Naproxen Dosing Guidelines
For adults with acute pain conditions, start with naproxen 500 mg (or naproxen sodium 550 mg) initially, followed by 500 mg every 12 hours or 250 mg every 6-8 hours as needed, not exceeding 1250 mg on day one and 1000 mg daily thereafter. 1
Adult Dosing by Indication
Acute Pain, Primary Dysmenorrhea, Tendonitis/Bursitis
- Initial dose: 500 mg naproxen (or 550 mg naproxen sodium for faster onset)
- Maintenance: 500 mg every 12 hours OR 250 mg every 6-8 hours
- Maximum: 1250 mg on day 1, then 1000 mg/day thereafter 1
The naproxen sodium formulation is preferred when rapid pain relief is desired due to faster absorption 1. Research confirms that 500/550 mg doses provide effective analgesia with a number-needed-to-treat of 2.7, meaning approximately half of patients achieve clinically meaningful pain relief 2.
Acute Gout
- Initial dose: 750 mg naproxen
- Maintenance: 250 mg every 8 hours until attack subsides 1
This higher loading dose strategy has been validated in clinical practice, with studies showing excellent or good response in 75% of patients when using this regimen 3.
Chronic Inflammatory Conditions (Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis)
- Standard dose: 250 mg, 375 mg, or 500 mg twice daily
- Maximum for limited periods: Up to 1500 mg/day for up to 6 months when higher anti-inflammatory activity is required 1
- Morning and evening doses need not be equal 1
For osteoarthritis specifically, non-prescription doses (660 mg/day in adults <65 years) demonstrate significant improvements in pain and physical function compared to placebo 4.
Elderly Patients (≥65 Years)
Reduce the dose to 440 mg/day (220 mg twice daily) for patients 65 years and older 4. This age-based dosing reflects the increased unbound plasma fraction of naproxen in elderly patients, even though total plasma concentration remains unchanged 1.
Key Considerations for Elderly:
- Use the lowest effective dose 1
- Monitor more closely for gastrointestinal bleeding (risk increases from 1 in 2,100 in adults <45 years to 1 in 110 in adults >75 years) 5
- Elderly patients tolerate peptic ulceration or bleeding less well 1
- Greater risk for renal toxicity due to age-related decline in renal function 1
Pediatric Dosing
Juvenile Arthritis (≥2 years)
- Dose: Approximately 10 mg/kg/day in 2 divided doses (5 mg/kg twice daily)
- Maximum: 15 mg/kg/day 1
- Naproxen oral suspension is recommended over tablets for accurate dosing 1
Safety and effectiveness have not been established in children under 2 years of age 1.
Renal Impairment
Naproxen is not recommended in patients with moderate to severe renal impairment (creatinine clearance <30 mL/min) 1. Since naproxen is substantially excreted by the kidney, dose reduction should be considered in patients with any degree of renal dysfunction 1.
Hepatic Impairment
Lower doses should be considered in patients with hepatic impairment 1. Caution is advised with chronic alcohol abuse or dependence 6.
Important Safety Considerations
Cardiovascular Risk
- Avoid NSAIDs with increasing COX-2 selectivity in patients with established cardiovascular disease 7
- Naproxen may have a more favorable cardiovascular profile compared to other NSAIDs, though data remains conflicting 8
- Do not use ibuprofen in patients taking aspirin for cardioprophylaxis as it blocks aspirin's antiplatelet effects 7
Gastrointestinal Protection
When NSAID therapy is necessary in high-risk patients:
- Add a proton pump inhibitor (PPI) for patients with history of peptic ulcer disease, age ≥65 years, or concurrent use of corticosteroids/anticoagulants 6, 5, 8
- PPIs reduce bleeding ulcer risk by approximately 75-85% in high-risk NSAID users 8
Duration of Therapy
Use the lowest effective dose for the shortest possible duration 6, 7. For acute conditions, treatment typically should not exceed 7-10 days without reassessment 9, 2.
Formulation Differences
Different naproxen formulations are not bioequivalent and have different onset times 1:
- Naproxen sodium: Faster absorption, preferred for acute pain
- Naproxen tablets: Standard formulation
- Naproxen delayed-release: Slower onset
- Naproxen suspension: Best for pediatric dosing
Consider formulation when changing products, as this affects onset of action 1.
Pregnancy and Lactation
Avoid naproxen during pregnancy, particularly in late pregnancy 1. It may cause closure of the ductus arteriosus, inhibit uterine contractions, and increase risk of uterine hemorrhage 1.
Avoid use in nursing mothers as naproxen appears in breast milk at approximately 1% of maternal plasma concentration 1.